Advanced search
Publication Cover
Current Medical Research and Opinion Volume 22, 2006 - Issue 2
Submit an article Journal homepage
125
Views
16
CrossRef citations to date
0
Altmetric
Review

Clinical experience and management considerations with long-acting risperidone

Eduard Parellada Clinic Schizophrenia Program, Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clinic de Barcelona, University of Barcelona, SpainCorrespondence[email protected]
Pages 241-255 | Accepted 15 Nov 2005, Published online: 14 Dec 2006

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Samuel Keith. (2009) Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost–effectiveness. Expert Review of Neurotherapeutics 9:1, pages 9-31.
Read now
Massimo Carlo Mauri, Martin Turner, Lucia S. Volonteri, Rossella Medori & Wolfgang Maier. (2009) Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg. International Journal of Psychiatry in Clinical Practice 13:1, pages 36-47.
Read now

Articles from other publishers (14)

Eduard Parellada & Miquel Bioque. (2016) Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia. CNS Drugs 30:8, pages 689-701.
Crossref
Mark Taylor & Ka Ying Bonnie Ng. (2012) Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Australian & New Zealand Journal of Psychiatry 47:7, pages 624-630.
Crossref
R. Jardri, F. Bonelli, F. Askenazy, N. Georgieff & P. Delion. (2013) Hallucinations de l’enfant et de l’adolescent. EMC - Psychiatrie 10:2, pages 1-12.
Crossref
Marja Hensen, Bart Heeg, Mickael Löthgren & Ben van Hout. (2010) Cost Effectiveness of Long-Acting Risperidone in Sweden. Applied Health Economics and Health Policy 8:5, pages 327-341.
Crossref
Eduard Parellada, Filippos Kouniakis, Aldona Siurkute, Andreas Schreiner & Liana Don. (2010) Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. International Clinical Psychopharmacology 25:3, pages 149-154.
Crossref
Renaud Jardri, Pierre Delion & Jean-Louis Goëb. (2010) Stratégies diagnostiques et thérapeutiques face aux hallucinations de l’enfant et de l’adolescent. La Presse Médicale 39:4, pages 420-430.
Crossref
Emmanuelle Deniau, Olivier Bonnot & David Cohen. (2008) Traitement médicamenteux des schizophrénies à début précoce. La Presse Médicale 37:5, pages 853-858.
Crossref
Robin Emsley, Rossella Medori, Liezl Koen, Petrus Paulus Oosthuizen, Dana J.H. Niehaus & Jonathan Rabinowitz. (2008) Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis. Journal of Clinical Psychopharmacology 28:2, pages 210-213.
Crossref
José M Olivares, Alfonso Rodriguez-Martinez, José A Burón, David Alonso-Escolano & Alexander Rodriguez-Morales. (2008) Cost-Effectiveness Analysis of Switching Antipsychotic Medication to Long-Acting Injectable Risperidone in Patients with Schizophrenia. Applied Health Economics and Health Policy 6:1, pages 41-53.
Crossref
Josè M. Olivares, Alfonso Rodriguez-Martinez, Josè A. Buron, David Alonso-Escolano & Alexander Rodriguez-Morales. (2013) Analisi costo-efficacia dello switch da un trattamento antipsicotico a risperidone iniettabile a rilascio prolungato in pazienti con schizofrenia. Giornale Italiano di Health Technology Assessment 1:1, pages 39-48.
Crossref
Soma Ganesan, Mario McKenna, Ric M. Procyshyn & Sheldon Zipursky. (2007) Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: A retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada). Current Therapeutic Research 68:6, pages 409-420.
Crossref
Samuel Keith. (2007) Dual Diagnosis of Substance Abuse and Schizophrenia: Improving Compliance with Pharmacotherapy. Clinical Schizophrenia & Related Psychoses 1:3, pages 259-269.
Crossref
Pierre Chue & Robin Emsley. (2007) Long-Acting Formulations of Atypical Antipsychotics. CNS Drugs 21:6, pages 441-448.
Crossref
Hans-Jürgen Möller. (2006) Long-acting risperidone: Focus on safety. Clinical Therapeutics 28:5, pages 633-651.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.